Magnesium repletion therapy improves lipid metabolism in hypomagnesemic renal transplant recipients

A pilot study

Bharat K. Gupta, Daniel Glicklich, Vivian A. Tellis

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background. Hypomagnesemia has been associated with hypertension, abnormal glucose and lipid metabolism, and accelerated atherosclerosis in nontransplant patients. Methods. In this prospective short-term pilot study, 14 hypomagnesemic renal transplant recipients with stable renal function were evaluated monthly over a 6-month interval. The first 3 months was the baseline observation period. During the second 3 months, MgO2 was administered to normalize the serum Mg level. Glucose tolerance, lipid levels, blood pressure, weight, and routine chemistries were assessed before and after Mg replacement. All others medications were held constant during the 6-month study. Results. Serum Mg levels increased to normal range after MgO2 therapy, which was well tolerated. There were significant decreases in total cholesterol, low density lipoprotein, and total cholesterol/high density lipoprotein ratio after 3 months of MgO2 therapy. Only three patients had abnormal baseline glucose tolerance tests. All three patients showed improved glucose tolerance after MgO2, but this was not statistically significant. Conclusions. Mg repletion may be an important ancillary therapy in hypomagnesemic renal transplant patients with hyperlipidemia.

Original languageEnglish (US)
Pages (from-to)1485-1487
Number of pages3
JournalTransplantation
Volume67
Issue number11
DOIs
StatePublished - Jun 15 1999

Fingerprint

Lipid Metabolism
Magnesium
Kidney
Glucose
Therapeutics
Glucose Tolerance Test
Hyperlipidemias
Serum
HDL Cholesterol
Atherosclerosis
Reference Values
Cholesterol
Observation
Blood Pressure
Hypertension
Transplants
Lipids
Weights and Measures
Transplant Recipients

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Magnesium repletion therapy improves lipid metabolism in hypomagnesemic renal transplant recipients : A pilot study. / Gupta, Bharat K.; Glicklich, Daniel; Tellis, Vivian A.

In: Transplantation, Vol. 67, No. 11, 15.06.1999, p. 1485-1487.

Research output: Contribution to journalArticle

Gupta, Bharat K. ; Glicklich, Daniel ; Tellis, Vivian A. / Magnesium repletion therapy improves lipid metabolism in hypomagnesemic renal transplant recipients : A pilot study. In: Transplantation. 1999 ; Vol. 67, No. 11. pp. 1485-1487.
@article{c8f49b7f0f0d4f3d99f9de1916692f32,
title = "Magnesium repletion therapy improves lipid metabolism in hypomagnesemic renal transplant recipients: A pilot study",
abstract = "Background. Hypomagnesemia has been associated with hypertension, abnormal glucose and lipid metabolism, and accelerated atherosclerosis in nontransplant patients. Methods. In this prospective short-term pilot study, 14 hypomagnesemic renal transplant recipients with stable renal function were evaluated monthly over a 6-month interval. The first 3 months was the baseline observation period. During the second 3 months, MgO2 was administered to normalize the serum Mg level. Glucose tolerance, lipid levels, blood pressure, weight, and routine chemistries were assessed before and after Mg replacement. All others medications were held constant during the 6-month study. Results. Serum Mg levels increased to normal range after MgO2 therapy, which was well tolerated. There were significant decreases in total cholesterol, low density lipoprotein, and total cholesterol/high density lipoprotein ratio after 3 months of MgO2 therapy. Only three patients had abnormal baseline glucose tolerance tests. All three patients showed improved glucose tolerance after MgO2, but this was not statistically significant. Conclusions. Mg repletion may be an important ancillary therapy in hypomagnesemic renal transplant patients with hyperlipidemia.",
author = "Gupta, {Bharat K.} and Daniel Glicklich and Tellis, {Vivian A.}",
year = "1999",
month = "6",
day = "15",
doi = "10.1097/00007890-199906150-00017",
language = "English (US)",
volume = "67",
pages = "1485--1487",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Magnesium repletion therapy improves lipid metabolism in hypomagnesemic renal transplant recipients

T2 - A pilot study

AU - Gupta, Bharat K.

AU - Glicklich, Daniel

AU - Tellis, Vivian A.

PY - 1999/6/15

Y1 - 1999/6/15

N2 - Background. Hypomagnesemia has been associated with hypertension, abnormal glucose and lipid metabolism, and accelerated atherosclerosis in nontransplant patients. Methods. In this prospective short-term pilot study, 14 hypomagnesemic renal transplant recipients with stable renal function were evaluated monthly over a 6-month interval. The first 3 months was the baseline observation period. During the second 3 months, MgO2 was administered to normalize the serum Mg level. Glucose tolerance, lipid levels, blood pressure, weight, and routine chemistries were assessed before and after Mg replacement. All others medications were held constant during the 6-month study. Results. Serum Mg levels increased to normal range after MgO2 therapy, which was well tolerated. There were significant decreases in total cholesterol, low density lipoprotein, and total cholesterol/high density lipoprotein ratio after 3 months of MgO2 therapy. Only three patients had abnormal baseline glucose tolerance tests. All three patients showed improved glucose tolerance after MgO2, but this was not statistically significant. Conclusions. Mg repletion may be an important ancillary therapy in hypomagnesemic renal transplant patients with hyperlipidemia.

AB - Background. Hypomagnesemia has been associated with hypertension, abnormal glucose and lipid metabolism, and accelerated atherosclerosis in nontransplant patients. Methods. In this prospective short-term pilot study, 14 hypomagnesemic renal transplant recipients with stable renal function were evaluated monthly over a 6-month interval. The first 3 months was the baseline observation period. During the second 3 months, MgO2 was administered to normalize the serum Mg level. Glucose tolerance, lipid levels, blood pressure, weight, and routine chemistries were assessed before and after Mg replacement. All others medications were held constant during the 6-month study. Results. Serum Mg levels increased to normal range after MgO2 therapy, which was well tolerated. There were significant decreases in total cholesterol, low density lipoprotein, and total cholesterol/high density lipoprotein ratio after 3 months of MgO2 therapy. Only three patients had abnormal baseline glucose tolerance tests. All three patients showed improved glucose tolerance after MgO2, but this was not statistically significant. Conclusions. Mg repletion may be an important ancillary therapy in hypomagnesemic renal transplant patients with hyperlipidemia.

UR - http://www.scopus.com/inward/record.url?scp=0033564454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033564454&partnerID=8YFLogxK

U2 - 10.1097/00007890-199906150-00017

DO - 10.1097/00007890-199906150-00017

M3 - Article

VL - 67

SP - 1485

EP - 1487

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 11

ER -